Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 1,252.9% in July

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 350,400 shares, anincreaseof1,252.9% from the June 30th total of 25,900 shares. Based on an average trading volume of 518,200 shares, the days-to-cover ratio is presently 0.7 days. Based on an average trading volume of 518,200 shares, the days-to-cover ratio is presently 0.7 days.

Astellas Pharma Stock Performance

OTCMKTS ALPMY opened at $10.57 on Monday. Astellas Pharma has a 12 month low of $8.37 and a 12 month high of $13.14. The company has a 50-day moving average of $9.71 and a 200-day moving average of $9.65. The company has a quick ratio of 0.85, a current ratio of 1.13 and a debt-to-equity ratio of 0.37.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.26. Astellas Pharma had a net margin of 4.34% and a return on equity of 19.76%. The company had revenue of $3.41 billion during the quarter, compared to analysts’ expectations of $3.20 billion. On average, analysts anticipate that Astellas Pharma will post 0.42 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.